Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments.

A marginally significant difference in favor of OCR on time to disability progression (34% risk reduction, P = .048) was also observed compared with patients on a NTZ treatment pathway ( Table 3 ).

also in 15,096 other papers

However, a numerical trend of fewer relapses and 24W-CDP events was observed for patients treated with IFN β-1a in the OPERA cohort.

also in 728 other papers